Nature Communications (Jul 2022)
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer
- Biyun Wang,
- Tao Sun,
- Yannan Zhao,
- Shusen Wang,
- Jian Zhang,
- Zhonghua Wang,
- Yue-E Teng,
- Li Cai,
- Min Yan,
- Xiaojia Wang,
- Zefei Jiang,
- Yueyin Pan,
- Jianfeng Luo,
- Zhimin Shao,
- Jiong Wu,
- Xiaomao Guo,
- Xichun Hu
Affiliations
- Biyun Wang
- Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
- Tao Sun
- Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute
- Yannan Zhao
- Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
- Shusen Wang
- Department of Medical Oncology, Sun Yat-Sen University Cancer Center, The State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
- Jian Zhang
- Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
- Zhonghua Wang
- Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
- Yue-E Teng
- Department of Medical Oncology, The First Hospital of China Medical University
- Li Cai
- Department of Medical Oncology, Harbin Medical University Cancer Hospital
- Min Yan
- Department of Breast Disease, Henan Breast Cancer Center, The affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
- Xiaojia Wang
- Department of Medical Oncology, Zhejiang Cancer Hospital
- Zefei Jiang
- Department of Medical Oncology, The Fifth Medical Center of Chinese PLA General Hospital
- Yueyin Pan
- Department of Medical Oncology, The First Hospital, Anhui Medical University
- Jianfeng Luo
- Department of Biostatistics, School of Public Health, Fudan University
- Zhimin Shao
- Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
- Jiong Wu
- Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
- Xiaomao Guo
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
- Xichun Hu
- Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
- DOI
- https://doi.org/10.1038/s41467-022-31704-7
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 7
Abstract
Platinum agents, such as carboplatin and cisplatin, have been recommended in combination with gemcitabine for the treatment of metastatic triple negative breast cancer (TNBC). Here the authors report the results of a randomized phase 3 trial to compare the efficacy of first-line nab-paclitaxel/cisplatin to gemcitabine/cisplatin in patients with TNBC.
